Yupelri Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Yupelri Indications
Indications
Yupelri Dosage and Administration
Adult
Children
Renal Impairment
No dosage adjustment is required in patients with renal impairment.
Severe renal impairment: Monitor for systemic antimuscarinic side effects.
Hepatic Impairment
Yupelri is not recommended in patients with any degree of hepatic impairment.
Systemic exposure of the active metabolite of revefenacin is increased in patients with moderate hepatic impairment.
Yupelri Contraindications
Not Applicable
Yupelri Boxed Warnings
Not Applicable
Yupelri Warnings/Precautions
Warnings/Precautions
Yupelri Pharmacokinetics
Absorption
Following inhaled administration, Cmax of revefenacin and its active metabolite occurred at the first postdose sampling time which ranged from 14 to 41 minutes after start of nebulization.
Distribution
Protein binding of revefenacin and its active metabolite in human plasma was on average 71% and 42%, respectively.
Elimination
Terminal half-life of revefenacin and its active metabolite after once-daily is 22 to 70 hours.
Yupelri Interactions
Interactions
Yupelri Adverse Reactions
Adverse Reactions
Yupelri Clinical Trials
Yupelri Note
Not Applicable
Yupelri Patient Counseling
Cost Savings Program
Images
